Navigation Links
Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/7/2012

WINSTON-SALEM, N.C., Nov. 7, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that John Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012, at 11:30 a.m. EST in New York City. 

A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/lz13/tngn or under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
2. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
7. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
8. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
11. PRA Expert to Present at Pharmacovigilance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... DIEGO, Oct. 31 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from fidaxomicin,s North American phase 3 study at the ... America (IDSA) in Philadelphia, PA. , (Logo: ... of the Division of Infectious Diseases, Chair of the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today that the Company will host a conference call ... Thursday, November 5, 2009 to discuss its third quarter ... participate in the call, please dial 800-860-2442 (domestic) or ...
... Pa., Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... , , -- Oppenheimer 20th Annual Healthcare Conference, to ... the Waldorf=Astoria hotel in New York. Management is scheduled, ... 3, and meet with, institutional investors ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... decade, Steve Stice has dedicated his research using embryonic ... degenerative diseases and debilitating injuries. His most recent discovery, ... stem cells, could now aid in national security. ... of Georgia animal science professor and Georgia Research Alliance ...
... CHAMPAIGN, Ill. -- By placing quantum dots on ... University of Illinois have demonstrated enhanced fluorescence intensity ... applications include high-brightness,light-emitting diodes, optical switches and personalized, ... a new way, said Brian Cunningham, a professor ...
... have discovered that a specific mutation of the COX2 ... of ovarian cancer, increasing womens susceptibility to developing the ... the findings are confirmed by further studies, it might ... as aspirin and ibuprofen, which are used already for ...
Cached Biology News:New use for stem cells found in war on terrorism 2New use for stem cells found in war on terrorism 3Researchers set new record for brightness of quantum dots 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3
...
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
MOUSE ANTI DUCK IgY LIGHT CHAIN...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
Biology Products: